---
figid: PMC4149909__nihms597526f2
figtitle: Gaps in conventional treatment of heart failure include deranged Beta-AR
  signaling, distorted Ca2+ cycling with depletion of SR Ca2+ levels, diastolic dysfunction,
  and cell death
organisms:
- Mus musculus
- Rattus norvegicus
- Oryctolagus cuniculus
- Canis lupus familiaris
- Sus scrofa
- Cricetus cricetus
- Homo sapiens
- Adeno-associated virus
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Sus scrofa
- Canis lupus familiaris
- Oryctolagus cuniculus
- Drosophila melanogaster
pmcid: PMC4149909
filename: nihms597526f2.jpg
figlink: /pmc/articles/PMC4149909/figure/F2/
number: F2
caption: 'Gaps in conventional treatment of heart failure include deranged β-AR signaling,
  distorted Ca2+ cycling with depletion of SR Ca2+ levels, diastolic dysfunction,
  and cell death. For each of these gaps, the molecular signaling pathways involved
  and potential gene therapy targets (depicted in color) are shown. (a) β-AR signaling:
  overexpression of the β2-AR, overexpression of AC VI, and inhibition of GRK2 by
  its C-terminal domain βARKct are all aimed at resensitizing the β-AR–G-protein–Ac
  interactome. (b) Ca2+ cycling: overexpression of SERCA2a, S100A1, or a dominant
  negative form of PLN or an shPLN are aimed at normalization of intracellular Ca2+
  handling. S100A1 also stabilizes the RyR, thereby reducing arrhythmogenic vulnerability.
  I-1 overexpression inhibits PP1, thereby also activating SERCA2a. (c) Diastolic
  dysfunction: overexpression of SERCA2a and S100A reduce diastolic cytosolic Ca2+
  levels and increase SR Ca2+ reuptake, thereby improving diastolic relaxation parameters.
  Overexpression of parvalbumin, an intracellular Ca2+ sink, leads to an energy-independent
  selective amelioration of diastolic dysfunction. (d) cell survival: β2-AR exerts
  antiapoptotic effects through the Gi-protein-mediated activation of the phosphatidylinositol-3′-kinase
  (PI3K)/Akt cell-survival pathway. Overexpression of a constitutively active form
  of Akt or PI3K and the abolishment of GRK2-mediated inhibition of Akt activate the
  survival pathway in heart failure. AC VI, adenylyl cyclase VI; β-AR, β-adrenergic
  receptor; βARKct, C-terminal domain of GRK2; GRK2, G-protein-coupled receptor kinase
  2; I-1, inhibitor-1; PI3K, phosphatidylinositol-3′-kinase; PLN, phospholamban; PP1,
  protein phosphatase type 1; RyR, ryanodine receptor; SERCA2a, sarcoplasmic reticulum
  Ca2+ ATPase; shPLN, short hairpin PLN; SR, sarcoplasmic reticulum.'
papertitle: 'Gene therapy targets in Heart Failure: the Path to translation.'
reftext: PWJ Raake, et al. Clin Pharmacol Ther. ;90(4):542-553.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7604687
figid_alias: PMC4149909__F2
figtype: Figure
redirect_from: /figures/PMC4149909__F2
ndex: 6c3518b7-df2e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4149909__nihms597526f2.html
  '@type': Dataset
  description: 'Gaps in conventional treatment of heart failure include deranged β-AR
    signaling, distorted Ca2+ cycling with depletion of SR Ca2+ levels, diastolic
    dysfunction, and cell death. For each of these gaps, the molecular signaling pathways
    involved and potential gene therapy targets (depicted in color) are shown. (a)
    β-AR signaling: overexpression of the β2-AR, overexpression of AC VI, and inhibition
    of GRK2 by its C-terminal domain βARKct are all aimed at resensitizing the β-AR–G-protein–Ac
    interactome. (b) Ca2+ cycling: overexpression of SERCA2a, S100A1, or a dominant
    negative form of PLN or an shPLN are aimed at normalization of intracellular Ca2+
    handling. S100A1 also stabilizes the RyR, thereby reducing arrhythmogenic vulnerability.
    I-1 overexpression inhibits PP1, thereby also activating SERCA2a. (c) Diastolic
    dysfunction: overexpression of SERCA2a and S100A reduce diastolic cytosolic Ca2+
    levels and increase SR Ca2+ reuptake, thereby improving diastolic relaxation parameters.
    Overexpression of parvalbumin, an intracellular Ca2+ sink, leads to an energy-independent
    selective amelioration of diastolic dysfunction. (d) cell survival: β2-AR exerts
    antiapoptotic effects through the Gi-protein-mediated activation of the phosphatidylinositol-3′-kinase
    (PI3K)/Akt cell-survival pathway. Overexpression of a constitutively active form
    of Akt or PI3K and the abolishment of GRK2-mediated inhibition of Akt activate
    the survival pathway in heart failure. AC VI, adenylyl cyclase VI; β-AR, β-adrenergic
    receptor; βARKct, C-terminal domain of GRK2; GRK2, G-protein-coupled receptor
    kinase 2; I-1, inhibitor-1; PI3K, phosphatidylinositol-3′-kinase; PLN, phospholamban;
    PP1, protein phosphatase type 1; RyR, ryanodine receptor; SERCA2a, sarcoplasmic
    reticulum Ca2+ ATPase; shPLN, short hairpin PLN; SR, sarcoplasmic reticulum.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ar
  - Adrb1
  - Bfar
  - ac
  - Tlx2
  - Cad
  - Dffb
  - Acod1
  - Cgct
  - Grk2
  - Pln
  - Pcsk1n
  - Tspan33
  - Ryr2
  - Akt1
  - Atp2a2
  - Bad
  - Nos3
  - CCNG1
  - CCNG2
  - AR
  - ADRB2
  - NR1H4
  - BFAR
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - TLX2
  - CAD
  - DFFB
  - ACOD1
  - CRYGD
  - GRK2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - GJA8
  - PLN
  - PUM3
  - PCSK1N
  - TSPAN33
  - RYR2
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - AKT1
  - AKT2
  - AKT3
  - BAD
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - NOS3
  - ENO4
  - Adcy6
  - Slc8a1
  - ATP2A2
  - ca
  - ar
  - B-H2
  - B-H1
  - hh
  - .na.character
  - na
  - vi
  - Sh
  - Calx
  - cad
  - Drep4
  - Ca-alpha1D
  - shg
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - sr
  - Pen
  - peng
  - peo
  - Galphai
  - Akt
  - SERCA
  - cass
---
